Insilico Medicine Secures Chinese Trial Approval for AI‑Driven Rentosertib Inhalation Therapy
Insilico Medicine’s Rentosertib inhalation therapy gains China trial approval, boosting its AI‑driven IPF drug pipeline and investor confidence.
- Insilico Medicine Cayman TopCo
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read